Company profile: NTx
1.1 - Company Overview
Company description
- Provider of a proprietary host-independent biological manufacturing and development platform.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NTx
Medrio
HQ: United States
Website
- Description: Provider of advanced electronic data capture (EDC) and e-clinical tools for complex clinical trials, offering real-time data access via dynamic reports, exports, and automated casebooks; supply chain optimization for coordinated dispensing aligned with manufacturing, packaging, labeling, and logistics; participant comprehension and engagement solutions; services to accelerate study timelines and improve clinical data integrity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medrio company profile →
RCT Logic
HQ: United States
Website
- Description: Provider of clinical trial design development and licensing for trials sponsored by industry, non-profit entities, and U.S. state governments, including the Sequential Parallel Comparison Design (SPCD) to reduce the detrimental impact of placebo response and address the placebo response problem.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RCT Logic company profile →
Frontier Medicines
HQ: United States
Website
- Description: Provider of a biopharmaceutical drug discovery platform integrating chemoproteomics, covalent chemistry, and machine learning to accelerate medicine development; programs include a dual KRASG12C inhibitor (FMC-376) targeting active and inactive forms in cancers and AutoTAC for autophagy-driven targeted degradation; tools span ML/AI prioritization, chemoproteomics to identify druggable hotspots, and a covalent fragment library.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Frontier Medicines company profile →
Silicon Therapeutics
HQ: United States
Website
- Description: Provider of fully integrated drug design, research and development using a physics-driven approach coupled to chemistry and biology R&D, with a pipeline including VTAMA (Tapinarof) for plaque psoriasis; Batoclimab for autoimmune diseases (MG, TED, CIDP, Graves' Disease); IMVT-1402 (Phase 1) subcutaneous injection; Brepocitinib for dermatomyositis and non-infectious uveitis (Phase 3 for some applications); and Namilumab for sarcoidosis (Phase 2).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silicon Therapeutics company profile →
Deciphex
HQ: Ireland
Website
- Description: Provider of AI-powered digital pathology solutions and services. Offers Diagnexia for remote diagnostic consultations and backlog reduction via a network of subspecialty pathologists, and Patholytix for accelerating drug development, including web-based workflow tools, Foresight decision support for toxicologic pathology, and AI analytics on whole slide images.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Deciphex company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NTx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NTx
2.2 - Growth funds investing in similar companies to NTx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NTx
4.2 - Public trading comparable groups for NTx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →